Tekla Capital Management’s Sutro Biopharma STRO Stock Holding History

Tekla Capital Management’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$457K	Hold	9,835	–	–	0.02%	148
2023 Q1	$454K	Sell	9,835 -4,918	-33%	-$312K	0.02%	152
2022 Q4	$1.19M	Sell	14,753 -1,639	-10%	-$114K	0.05%	131
2022 Q3	$910K	Hold	16,392	–	–	0.04%	135
2022 Q2	$854K	Hold	16,392	–	–	0.03%	138
2022 Q1	$1.35M	Sell	16,392 -16,393	-50%	-$1.56M	0.05%	136
2021 Q4	$4.88M	Sell	32,785 -7,230	-18%	-$1.3M	0.16%	102
2021 Q3	$7.56M	Hold	40,015	–	–	0.24%	87
2021 Q2	$7.44M	Sell	40,015 -17,367	-30%	-$3.4M	0.24%	101
2021 Q1	$13.1M	Sell	57,382 -12,870	-18%	-$3.05M	0.45%	60
2020 Q4	$15.3M	Buy	70,252 +6,125	+10%	+$1.01M	0.54%	52
2020 Q3	$6.45M	Hold	64,127	–	–	0.24%	91
2020 Q2	$4.98M	Hold	64,127	–	–	0.19%	101
2020 Q1	$6.54M	Hold	64,127	–	–	0.3%	70
2019 Q4	$7.05M	Hold	64,127	–	–	0.27%	81
2019 Q3	$5.83M	Hold	64,127	–	–	0.25%	74
2019 Q2	$7.3M	Hold	64,127	–	–	0.3%	73
2019 Q1	$7.3M	Buy	64,127 +41,137	+179%	+$4.28M	0.3%	71
2018 Q4	$2.07M	Sell	22,990 -2,010	-8%	-$243K	0.09%	127
2018 Q3	$3.75M	Buy	+25,000	New	+$3.77M	0.14%	111

Other funds holding STRO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Tekla Capital Management's STRO Position: Q2 2023 in Review

Tekla Capital Management held its Sutro Biopharma (STRO) position steady in Q2 2023 at 9,835 shares worth $457K. The position accounts for 0.02% of the portfolio, ranked #148.

Tekla Capital Management first reported a position in STRO in Q3 2018 and has held it in 20 quarters since. The position peaked at $15.3M in Q4 2020. 120 funds tracked by Wall St. Rank hold STRO as of Q2 2023.

Tekla Capital Management held 9,835 shares of Sutro Biopharma worth $457K as of Q2 2023.
Tekla Capital Management left its Sutro Biopharma share count unchanged in Q2 2023.
Sutro Biopharma made up 0.02% of Tekla Capital Management's portfolio in Q2 2023, its #148 holding.
Tekla Capital Management first reported a position in Sutro Biopharma in Q3 2018 and has held it in 20 quarters since.
Tekla Capital Management's Sutro Biopharma position peaked at $15.3M in Q4 2020.
120 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.